Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
| The first 150 words of the full text of this article appear below. |
EDITOR
Because of a series of questions I have received about the
current clinical use of human albumin in critically ill patients, I
wish to clarify the message that I intended my editorial last week to
convey.1
Given the current evidence as summarised by the Cochrane albumin
reviewers group,2 the use of albumin does not need be
stopped totally and immediately yet. The use of albumin in clinical
practice has changed since the trials that were included in the
systematic review. In the past few years the quality of albumin
solutions has improved; contaminations and clinically relevant side
effects are further limited. Although there is currently no evidence
from clinical studies to support this, albumin given for the right
indications at the right dose and infusion rate, with an optimal
product being used, may be safe and effective and could lead to better
outcomes than were found by the
Read all Rapid Responses